55th European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN 2023) Annual Meeting

Vienna, Austria 17 May 2023 - 20 May 2023

Another IBAT inhibitor makes its case in large PFIC trial

30 Jun 2023 by

The ileal bile acid transporter (IBAT) inhibitor maralixibat appears to quell itching and reduce serum bile acid concentration in children with progressive familial intrahepatic cholestasis (PFIC), while having a tolerable safety profile, according to data from the phase III MARCH-PFIC trial said to be the largest to date.

Another IBAT inhibitor makes its case in large PFIC trial

30 Jun 2023

Long-term data support teduglutide safety for SBS-IF

30 Jun 2023 by

In a pooled analysis of two long-term paediatric extension trials evaluating short bowel syndrome-associated intestinal failure (SBS-IF), the glucagon-like peptide-2 analogue teduglutide (TED) demonstrated a safety profile that aligned with previous data.

Long-term data support teduglutide safety for SBS-IF

30 Jun 2023

$Faecal transplant helps teens with refractory IBS$

Faecal transplant helps teens with refractory IBS

29 Jun 2023 by

For adolescents with treatment-refractory irritable bowel syndrome (IBS), faecal microbiota transplantation (FMT) is safe and beneficial, easing abdominal pain and improving health-related quality of life, according to a study presented at ESPGHAN 2023.

Faecal transplant helps teens with refractory IBS

29 Jun 2023

Mediterranean diet counselling may help counter overweight/obesity in the offspring

23 Jun 2023 by

A personalized nutritional counselling targeting adherence to the Mediterranean diet (MD) during pregnancy may be an effective strategy against childhood overweight/obesity, findings from the PREMEDI study have shown.

Mediterranean diet counselling may help counter overweight/obesity in the offspring

23 Jun 2023

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023 by

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023

Teduglutide effective in children with SBS, but still costly

15 Jun 2023 by

Use of teduglutide is effective against short bowel syndrome (SBS) in paediatric patients, although some children need a longer duration of treatment to achieve enteral autonomy, according to a Spain study presented at ESPGHAN 2023. Predictive factors of response to treatment have not been identified.

Teduglutide effective in children with SBS, but still costly

15 Jun 2023

Dupilumab shows benefit in young children with EoE

15 Jun 2023 by

Treatment with dupilumab significantly improves histologic and endoscopic measures of eosinophilic esophagitis (EoE) in young children aged 1–11 years, according to the phase III EoE KIDS trial presented at ESPGHAN 2023.

Dupilumab shows benefit in young children with EoE

15 Jun 2023

Add-on L. reuteri mitigates diarrhoea risk in children on antibiotics

13 Jun 2023 by

Adding the probiotic Limosilactobacillus reuteri (L. reuteri) DSM 17938 to antibiotic therapy significantly reduced the incidence of antibiotic-associated diarrhoea (AAD) in children with acute otitis media or acute bacterial sinusitis in the PEARL study presented at ESPGHAN 2023.

Add-on L. reuteri mitigates diarrhoea risk in children on antibiotics

13 Jun 2023